AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21227601 — intervention group
Group type: EXPERIMENTAL
Intervention: Days of use during treatment
Number of subjects: 0
Study 18382901 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (Aerodiol)
Number of subjects: 30
Study 18382901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16480471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine 30 mg/ml
Number of subjects: 40
Study 16480471 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 20 mg/ml with 5 microg/ml epinephrine
Number of subjects: 40
Study 16480471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine
Number of subjects: 40
Study 16480471 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 40
Study 12900689 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg x kg‐1 of caffeine in the AM and 2.5 mg x kg‐1 of caffeine in the PM (trial A)
Number of subjects: 9
Study 12900689 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg x kg‐1 of caffeine in the AM and placebo in the PM (trial C)
Number of subjects: 9
Study 12900689 — intervention group
Group type: COMPARATOR
Intervention: Placebo in both AM and PM (trial B)
Number of subjects: 9
Study 12900689 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in the AM and 5 mg x kg‐1 of caffeine in the PM (trial D)
Number of subjects: 9
Study 12900689 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the AM and placebo in the PM (trial B)
Number of subjects: 9
Study 11180196 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroxin (400 mg)
Number of subjects: 18
Study 11180196 — intervention group
Group type: COMPARATOR
Intervention: Noroxin (400 mg)
Number of subjects: 18
Study 9420044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole (200 mg) administered as four 1-hour infusions on days 1-2, followed by daily 1-hour infusions of 200 mg from days 3-7.
Number of subjects: 16
Study 9420044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution (200 mg once daily) after i.v. treatment.
Number of subjects: 16
Study 9420044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution (200 mg twice daily) after i.v. treatment.
Number of subjects: 16
Study 9420044 — intervention group
Group type: COMPARATOR
Intervention: Intravenous treatment phase compared to oral treatment phase.
Number of subjects: 16
Study 8237748 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (aminophylline, mean concentration 16.1 mg/L)
Number of subjects: 16
Study 8237748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3698783 — intervention group
Group type: EXPERIMENTAL
Intervention: Home teaching
Number of subjects: 393
Study 3698783 — intervention group
Group type: COMPARATOR
Intervention: Control (no home teaching)
Number of subjects: 393
Study 31330767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentha longifolia
Number of subjects: 29
Study 31330767 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtica dioica
Number of subjects: 29
Study 31330767 — intervention group
Group type: EXPERIMENTAL
Intervention: Viola odorata
Number of subjects: 29
Study 31330767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29033381 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg intravenous infusion once yearly for 2 years
Number of subjects: 102
Study 29033381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 27600465 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI flow grade ≤1 before PCI
Number of subjects: 738
Study 24866597 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging guided in‐bore biopsy
Number of subjects: 132
Study 24866597 — intervention group
Group type: COMPARATOR
Intervention: Standard systematic transrectal ultrasound guided biopsy
Number of subjects: 132
Study 24866597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both methods
Number of subjects: 132
Study 22621776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal BDP HFA 80 μg
Number of subjects: 30
Study 22621776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal BDP HFA 320 μg
Number of subjects: 30
Study 22621776 — intervention group
Group type: COMPARATOR
Intervention: Orally inhaled BDP HFA 320 μg
Number of subjects: 30
Study 22621776 — intervention group
Group type: COMPARATOR
Intervention: Intranasal BDP HFA 320 μg vs Orally inhaled BDP HFA 320 μg
Number of subjects: 30
Study 22621776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal BDP HFA 80 μg vs 320 μg
Number of subjects: 30
Study 19880495 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-specific cytotoxic T lymphocytes (CTLs) prophylaxis
Number of subjects: 114
Study 19880495 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-specific cytotoxic T lymphocytes (CTLs) treatment
Number of subjects: 114
Study 17655686 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/10-, 10/20-, 10/40-, or 10/80-mg
Number of subjects: 0
Study 17655686 — intervention group
Group type: COMPARATOR
Intervention: SIMVA 10-, 20-, 40-, or 80-mg
Number of subjects: 0
Study 17655686 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA
Number of subjects: 0
Study 15131430 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed wound suction drain
Number of subjects: 83
Study 15131430 — intervention group
Group type: COMPARATOR
Intervention: No closed wound suction drain
Number of subjects: 83
Study 12235450 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (250 mg daily) plus chloroguanide (100 mg daily)
Number of subjects: 119
Study 12235450 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (250 mg weekly)
Number of subjects: 119
Study 9828753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 170
Study 9828753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study 8205446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 163
Study 8205446 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepacol
Number of subjects: 163
Study 8205446 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 163
Study 8205446 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 163
Study 2686421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg IV every 12 hours followed by 500 mg orally every 12 hours)
Number of subjects: 47
Study 2686421 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g IV every 8 to 12 hours)
Number of subjects: 47
Study 30679301 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery and progressive muscle relaxation
Number of subjects: 208
Study 30679301 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 208
Study 28925467 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 120
Study 26311325 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for each dose of medicine in addition to the standard of care.
Number of subjects: 200
Study 26311325 — intervention group
Group type: COMPARATOR
Intervention: Standard of care as per institutional guidelines.
Number of subjects: 200
Study 24146460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sophora flower formula
Number of subjects: 0
Study 24146460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21546500 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride plus low-dose interleukin-2
Number of subjects: 320
Study 21546500 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 320
Study 18192453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoscopic endomicroscopy with targeted biopsies
Number of subjects: 0
Study 18192453 — intervention group
Group type: COMPARATOR
Intervention: Pan-colonic chromoscopy assisted colonoscopy
Number of subjects: 0
Study 16950752 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.4 mg/day for males, 0.6 mg/day for females) for 12 months
Number of subjects: 21
Study 16950752 — intervention group
Group type: COMPARATOR
Intervention: Control values from fourteen healthy subjects matched by age, sex, and BMI
Number of subjects: 21
Study 14597992 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ultrasound screening for proximal and distal thrombosis
Number of subjects: 346
Study 14597992 — intervention group
Group type: COMPARATOR
Intervention: Prolonged prophylaxis with LMWH
Number of subjects: 346
Study 16841668 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinghua Weikang Capsule (JWC) high-dose 160 mg, 3 times per day for 14 days
Number of subjects: 90
Study 16841668 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinghua Weikang Capsule (JWC) low-dose 80 mg, 3 times per day for 14 days
Number of subjects: 90
Study 16841668 — intervention group
Group type: COMPARATOR
Intervention: Domperidone 10 mg, 3 times per day for 14 days (Control group)
Number of subjects: 90
Study 10472523 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 9
Study 10472523 — intervention group
Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 9
Study 8735998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise (n = 18)
Number of subjects: 34
Study 8735998 — intervention group
Group type: COMPARATOR
Intervention: Videotape watching (n = 16)
Number of subjects: 34
Study 1836918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms intradermal injection
Number of subjects: 425
Study 1836918 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms intramuscular injection
Number of subjects: 425
Study 6120717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.5, 1.0, and 2.0 mg)
Number of subjects: 6
Study 6120717 — intervention group
Group type: EXPERIMENTAL
Intervention: Camazepam (10-20 mg)
Number of subjects: 6
Study 6120717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31647535 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐AVR
Number of subjects: 5801
Study 31647535 — intervention group
Group type: COMPARATOR
Intervention: AVR
Number of subjects: 5801
Study 27817985 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer fabric
Number of subjects: 6
Study 27817985 — intervention group
Group type: COMPARATOR
Intervention: Cotton fabric
Number of subjects: 6
Study 25468682 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (1 mg/kg/day)
Number of subjects: 24
Study 25468682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24699217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) with positive end-expiratory pressure (PEEP)
Number of subjects: 24
Study 23127528 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of serum CA19-9
Number of subjects: 90
Study 20214327 — intervention group
Group type: EXPERIMENTAL
Intervention: YHF + Omeprazole
Number of subjects: 46
Study 20214327 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 46
Study 18085908 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas + PATH
Number of subjects: 266
Study 15000770 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovo insulin doser
Number of subjects: 217
Study 15000770 — intervention group
Group type: COMPARATOR
Intervention: NovoPen 3
Number of subjects: 217
Study 11133319 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults
Number of subjects: 0
Study 11133319 — intervention group
Group type: COMPARATOR
Intervention: Elderly adults
Number of subjects: 0
Study 11133319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 0
Study 9880943 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole sulphoxide in lipidic matrix of Gelucire 44/14 (ABZSLM)
Number of subjects: 8
Study 9880943 — intervention group
Group type: COMPARATOR
Intervention: albendazole (ABZLM)
Number of subjects: 8
Study 7972311 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml at 0, 2, 4, 8 and 12 h)
Number of subjects: 9
Study 7972311 — intervention group
Group type: COMPARATOR
Intervention: Control (diltiazem 120 mg orally without grapefruit juice)
Number of subjects: 9
Study 2657428 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 0.75 mg/kg/day (n = 33)
Number of subjects: 103
Study 2657428 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 1.5 mg/kg/day (n = 34)
Number of subjects: 103
Study 2657428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 103
Study 2657428 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisone (1.5 mg/kg/day)
Number of subjects: 103
Study 30726692 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline (100 mg intravenously every 12 hours for two doses, then 100 mg intravenously every 24 hours; transition to oral 300 mg every 24 hours after 3 days)
Number of subjects: 774
Study 30726692 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg intravenously every 24 hours; transition to oral 400 mg every 24 hours after 3 days)
Number of subjects: 774
Study 30726692 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 774
Study 30726692 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 774
Study 29102674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ologen (biodegradable collagen matrix)
Number of subjects: 14
Study 29102674 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (control)
Number of subjects: 14
Study 26482031 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure incision therapy device applied for 5-7 days
Number of subjects: 340
Study 26482031 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 340
Study 22429618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM) - cyclopentolate 0.1%, phenylephrine 1.5%, xylocaine 1%
Number of subjects: 60
Study 22429618 — intervention group
Group type: COMPARATOR
Intervention: Topical mydriatics (TM) - cyclopentolate 0.85%, phenylephrine 1.5%, xylocaine 1% intracamerally
Number of subjects: 60
Study 22429618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM)
Number of subjects: 60
Study 22429618 — intervention group
Group type: COMPARATOR
Intervention: Topical mydriatics (TM)
Number of subjects: 60
Study 21224217 — intervention group
Group type: EXPERIMENTAL
Intervention: Very dim light history
Number of subjects: 0
Study 21224217 — intervention group
Group type: COMPARATOR
Intervention: Typical indoor room illuminance
Number of subjects: 0
Study 20472226 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridotomy
Number of subjects: 158
Study 20472226 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridotomy plus iridoplasty
Number of subjects: 158
Study 17389556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper back
Number of subjects: 40
Study 17389556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to chest
Number of subjects: 40
Study 17389556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to abdomen
Number of subjects: 40
Study 17389556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to thigh
Number of subjects: 40
Study 17389556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper arm
Number of subjects: 40
Study 16314774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrin sulphate 4% (DS4%)
Number of subjects: 100
Study 16314774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrin sulphate 1% (DS1%)
Number of subjects: 100
Study 16314774 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 100
Study 16314774 — intervention group
Group type: COMPARATOR
Intervention: No gel
Number of subjects: 100
Study 11875330 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with 2 mg estradiol valerate and 1 mg cyproterone acetate (n = 15)
Number of subjects: 75
Study 11875330 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with 2 mg estradiol valerate and 75 mug levonorgestrel (n = 15)
Number of subjects: 75
Study 11875330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 75
Study 10434537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermaxillary block lasting more than 25 days (Group A)
Number of subjects: 40
Study 10434537 — intervention group
Group type: COMPARATOR
Intervention: Intrafocal osteosynthesis with immobilisation lasting less than 15 days (Group B)
Number of subjects: 40
Study 7766868 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal vision
Number of subjects: 0
Study 7766868 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed vision (strobe light, blackened goggles, visual conflict dome)
Number of subjects: 0
Study 2125460 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg daily
Number of subjects: 12
Study 2125460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2125460 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 12
Study 2125460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12
Study 6775297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lénitral 2.5 mg (2 capsules)
Number of subjects: 30
Study 6775297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lénitral 7.5 mg (1 capsule)
Number of subjects: 30
Study 6775297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6775297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin 0.6 mg
Number of subjects: 30
Study 30183546 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoking freedom condition (BYAF technique)
Number of subjects: 0
Study 30183546 — intervention group
Group type: COMPARATOR
Intervention: Direct requests
Number of subjects: 0
Study 28882235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 21162
Study 28882235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study 25495523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperechoic needles
Number of subjects: 200
Study 25495523 — intervention group
Group type: COMPARATOR
Intervention: Standard needles
Number of subjects: 200
Study 25495523 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthetic experience ≥ 1 year
Number of subjects: 200
Study 25495523 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthetic experience < 1 year
Number of subjects: 200
Study 22460738 — intervention group
Group type: EXPERIMENTAL
Intervention: white fissure sealant with filler particles (Fissurit F, Voco)
Number of subjects: 60
Study 22460738 — intervention group
Group type: EXPERIMENTAL
Intervention: clear fissure sealant without filler particles (Fissurit, Voco)
Number of subjects: 60
Study 22460738 — intervention group
Group type: EXPERIMENTAL
Intervention: novel experimental fissure sealant with nano-filler particles (Voco)
Number of subjects: 60
Study 21867540 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid infusion
Number of subjects: 9978
Study 19262211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 46
Study 19262211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17302019 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 9
Study 17302019 — intervention group
Group type: COMPARATOR
Intervention: Placebo or conservative treatment
Number of subjects: 9
Study 15197664 — intervention group
Group type: EXPERIMENTAL
Intervention: E-5564, an injectable endotoxin antagonist
Number of subjects: 0
Study 11325088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (15-30 mg IV q 6 h)
Number of subjects: 65
Study 11325088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 9215655 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcriptase inhibitor therapy
Number of subjects: 22
Study 9215655 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal group (no intervention)
Number of subjects: 22
Study 7952550 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 19
Study 7952550 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 19
Study 3322728 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction in intermediate‐acting insulin dose
Number of subjects: 9
Study 3322728 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction in soluble insulin dose
Number of subjects: 9
Study 3322728 — intervention group
Group type: EXPERIMENTAL
Intervention: extra caloric intake (1700 kJ) 1 h after exercise
Number of subjects: 9
Study 3322728 — intervention group
Group type: COMPARATOR
Intervention: no change (control)
Number of subjects: 9
Study 31079163 — intervention group
Group type: EXPERIMENTAL
Intervention: ArthroBox® training group (n=10)
Number of subjects: 19
Study 31079163 — intervention group
Group type: COMPARATOR
Intervention: Non-training group (n=9)
Number of subjects: 19
Study 29121789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 33
Study 29903120 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk enriched with phytosterol ester (PS group)
Number of subjects: 179
Study 29903120 — intervention group
Group type: COMPARATOR
Intervention: Normal milk group
Number of subjects: 179
Study 29903120 — intervention group
Group type: COMPARATOR
Intervention: Non-dairy group
Number of subjects: 179
Study 25809163 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy with radiofrequency destruction (RFD) of the facet nerves
Number of subjects: 113
Study 25809163 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 113
Study 22776750 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 80
Study 22776750 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 80
Study 20423835 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 30